8-K current report · filed Nov 9, 2026

Orthofix Medical Inc. (OFIX) 8-K Current Report: November 9, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2OFIX overview

Short answer

Orthofix Medical Inc. (OFIX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 results covered the period ended September 30, 2026, with detailed financial figures contained in Exhibit 99.1.

Orthofix Medical Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 results covered the period ended September 30, 2026, with detailed financial figures contained in Exhibit 99.1
  • Management emphasizes adjusted EBITDA, free cash flow, constant-currency sales and adjusted earnings for operating performance analysis
  • Non-GAAP exclusions include SeaSpine merger costs, M6 product-line exit effects, strategic investments, litigation and employee-transition costs
  • A 28% normalized long-term tax rate underpins adjusted 2026 results, potentially differing materially from GAAP tax expense
  • Investors should compare adjusted metrics with GAAP results because excluded items include cash costs and recurring compensation expense

Item 7.01 · Regulation FD Disclosure

  • Investor-relations presentation designated for use with investors and analysts through December 31, 2026
  • Exhibit 99.2 likely outlines Orthofix’s corporate narrative, strategy, and investor messaging for fiscal 2026

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net sales $207.9M, up 1.1% reported, while pro forma constant-currency growth reached 2.3%
  • Spine growth weakened to 0.9%, offset by Limb Reconstruction growth of 8.5% and Therapeutic Solutions growth of 4.5%
  • Net loss narrowed to $6.1M from $22.8M, while adjusted EBITDA rose to $26.0M, or 12.5% of pro forma sales
  • Full-year sales guidance reduced to $825M-$830M from $845M-$855M, signaling continued U.S. Spine execution pressure
  • Adjusted EBITDA guidance cut to $86M-$88M from $95M-$98M, with actions targeting instrument availability and asset productivity

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 sales $207.9M, up 2% year over year constant currency, with Limb Reconstruction +9.4% and Therapeutic Solutions +4.5%
  • U.S. Spine sales fell 4.3%, reflecting market softness, supplier delays, inventory constraints and instrument-set shortages
  • Adjusted EBITDA $26.0M, 12.5% margin, versus $24.6M and 12.1% in Q3 2025, despite gross margin declining to 70.7% from 72.1%
  • 2026 guidance reduced to $825M–$830M sales and $86M–$88M adjusted EBITDA, from $845M–$855M and $95M–$98M
  • Management prioritizing U.S. Spine execution, inventory productivity and free cash flow improvement, with positive FCF targeted as a key valuation catalyst

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Orthofix Medical Inc. 8-K filings

Get the next OFIX 8-K as it lands

Follow OFIX for push alerts, or ask the research agent what this filing means.